| Patient | Judy Garland |
|---|---|
| Date of birth | 1922-06-10 |
| Identifiers | MRN HR-ML005-SYN-TD; SSN (made up) 000-05-6127 |
| Document date | 1955-06-29 |
| Author | Margaret Ellsworth-Diaz, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
One-week review, seen the same day by addiction medicine. [S]
Ms. Garland returns one week after intake and is seen by Dr. Grünewald of addiction medicine on the same day. She has taken secobarbital 200 mg at bedtime from the seven-day supply on six nights; on one night before a recording session she took a third capsule when she could not sleep, and she told us so herself. She has had no daytime shakes, sweats, or seizure-like episodes. She has taken dextroamphetamine 10 mg each morning and no extra doses, and she has felt flat and tired in the afternoons. She has taken sertraline 25 mg daily without nausea or headache. She brought 38 unused secobarbital capsules and 22 dextroamphetamine tablets from earlier prescriptions, which she placed in the pharmacy take-back box with the nurse today. She keeps this week's supply in a locked box. She has two weeks free of performances from next week and would like to use them for the change. [S]
| Element | Detail |
|---|---|
| Secobarbital | 200 mg at bedtime on six nights; 300 mg on one night |
| Withdrawal symptoms | None |
| Dextroamphetamine | 10 mg each morning; no extra doses |
| Sertraline | 25 mg daily for a week; no side effects |
| Take-back | 38 secobarbital capsules and 22 dextroamphetamine tablets returned today |
| Work | Two weeks without performances from next week |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired in the afternoons; no fever |
| Neurological | Negative | No tremor, unsteadiness or seizure-like episodes |
| Psychiatric | Positive | Low mood and worry, a little better; no thoughts of suicide or self-harm |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicine | Two capsules at bedtime; no extra doses | Oral route | 1955-06-22 to 1955-07-06 | completed | S |
| Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energy | One tablet each morning | Oral route | 1955-06-22 to 1955-07-20 | completed | S |
| Sertraline 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1955-06-22 to 1955-06-29 | completed | S |
| Sertraline 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1955-06-29 | active | S |
| Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks | 150 mg intramuscularly every 13 weeks | Intramuscular route | 1955-06-22 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1955-06-29 | Body height | 151 | cm | S |
| 1955-06-29 | Body weight | 46.8 | kg | S |
| 1955-06-29 | Body mass index (BMI) [Ratio] | 20.5 | kg/m2 | S |
| 1955-06-29 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1955-06-29 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1955-06-29 | Heart rate | 92 | /min | S |
| 1955-06-29 | Respiratory rate | 16 | /min | S |
| 1955-06-29 | Body temperature | 36.7 | Cel | S |
| 1955-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
Vital signs recorded on 1955-06-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert; blood pressure 124/80, pulse 92 |
| Neurological | No tremor; no nystagmus; gait steady |
| Psychiatric | Engaged and candid; no signs of intoxication or withdrawal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate, with physiological dependence; began with sleeping pills given in adolescence; synthetic modern episode linked to her documented lifelong dependence on prescribed sleeping pills | active | confirmed | F13.20 | S — Synthetic modern coding. Tolerance and withdrawal are not counted toward the diagnosis for a medicine taken under medical supervision; five other criteria are met. Person-first language; not a claim about her real diagnosis. |
| Stimulant use disorder (prescribed amphetamine), mild; began with stimulants given in adolescence for weight and energy; synthetic modern episode linked to her documented pep pills | active | confirmed | F15.10 | S — Synthetic modern coding; DSM-5-TR mild stimulant use disorder maps to F15.10. Tolerance and withdrawal are not counted for a supervised prescription. |
| Chronic insomnia disorder, long-standing, with sleep tied to sleeping pills since adolescence | active | confirmed | G47.00 | S — Synthetic modern diagnosis anchored to the documented sleeping pills. |
| Contraception three months after childbirth while starting an enzyme-inducing drug: injectable progestin chosen because barbiturates, including any used for the withdrawal, weaken contraceptive pills, patches, rings and implants | active | confirmed | Z30.013 | S — Synthetic contraception need; the birth is documented. |
| Major depressive disorder, single episode, moderate, with anxious distress; Mood Disorder Questionnaire negative and no history of mania or hypomania | active | confirmed | F32.1 | S — Synthetic modern diagnosis; not a claim about her real mood. The roster's bipolar disorder lead is not supported by the sources read and is not used. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Barbiturate dose, adherence, extra doses, and withdrawal signs (tremor, sweating, pulse, sleep, seizure warning signs) | Every visit | Completed today | 200 mg on six nights and 300 mg on one; no withdrawal signs |
| Referral | Setting for barbiturate withdrawal | Before any reduction | Ordered | Four-day admission to the addiction medicine service planned for next week, as advised today |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's prescriptions since intake |
| Laboratory | Urine drug testing, explained as part of care | At the start, after the change to phenobarbital, and periodically during the taper | Up to date | At intake: barbiturates and amphetamine only; no opioids, fentanyl or benzodiazepines |
| Medication safety | Limited dispensing, locked storage and take-back of unused capsules | Seven days at first, then two weeks at a time | Completed today | Seven-day supply; locked box; 38 capsules and 22 tablets taken back today |
| Medication safety | Stimulant dose, extra doses, cravings, and blood pressure and pulse | Every visit | Completed today | 10 mg each morning, no extra doses; blood pressure 124/80, pulse 92 |
| Survey | CBT for insomnia, sleep diary and Insomnia Severity Index | Weekly CBT-I sessions; sleep diary and index at each visit | Completed today | First CBT-I session booked; sleep diary started; Insomnia Severity Index 21 (moderate) |
| Medication safety | New hypnotic (benzodiazepine, Z-drug, trazodone or antihistamine) | Not recommended as a replacement | Not indicated | No new hypnotic during the barbiturate taper |
| Survey | Depression (PHQ-9) | At least monthly during acute treatment | Up to date | PHQ-9 14 a week ago; next at the four-week visit |
| Medication safety | Sertraline adherence and side effects | Two weeks after starting or changing the dose, then each visit | Completed today | No side effects on 25 mg; increased to 50 mg |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, means safety and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | C-SSRS screen negative since the last visit; unused capsules returned; the 988 Suicide & Crisis Lifeline in her phone |
| Self-management | Psychotherapy | Weekly | Completed today | First session this week |
| Examination | Weight, meals and disordered-eating screen, without a weight target | Every visit | Completed today | Weight 46.8 kg; eating one or two meals a day |
| Medication safety | Naloxone | Reassess at every visit and whenever an opioid is prescribed | Not indicated | No opioids prescribed or used; naloxone would not reverse a barbiturate |
| Referral | Addiction medicine consultation | At the start of treatment | Completed today | Seen by Dr. Grünewald today |
Goal progress:
Guideline basis: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016); Prescription Drug Monitoring Programs (PDMPs) (2026); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Hospital admission in one week. Four-week review after discharge. Weekly psychotherapy and CBT-I. Next scheduled visit 1955-07-20: four-week review eleven days after a supervised hospital change from secobarbital to phenobarbital: starting the outpatient taper and the stimulant taper. [S]